Cervical Cancer Diagnostics Market Size is expected to record considerable expansion between 2022 and 2028 owing to the increasing demand for a number of tests such as colposcopy and pelvic exams. The rising preference for colposcopes is because they provide physicians with the advantage of an enlarged view of the areas for observing any abnormal tissue. On the other hand, pelvic exams enable a healthcare professional to conduct the manual examination of the cervix, vagina, ovaries, fallopian tubes, uterus, and rectum for things such as bumps or nodules, that could be explored in greater detail with the help of imaging technology.
On the basis of type, the market is estimated to register substantial growth from the pap smear segment through 2028. The tests are mainly deployed for the presence of cancerous or precancerous cells on the cervix and is one of the most advocated screening procedures for the disease. As per the recommendations of the American Cancer Society, screening should start at the age of 25. In addition, frequent tests are recommended for women who are HIV positive and have a weakened immune system from an organ transplant or chemotherapy. These factors are set to propel the demand for pap tests through the forecast period.
Based on end-use, the diagnostic centers segment is anticipated to account for a commendable share in the market up to 2028. This is predominantly credited to the availability of cancer specialists in the deployment of the most advanced techniques for the diagnosis of cervical cancers. Furthermore, these centers also enable women, who have signs and symptom of cervical cancer to undergo a range of diagnostic tests including pap test, HPV test, and others.
North America cervical cancer diagnostics market is projected to record lucrative growth through 2028. This is due to the formulation of various cancer care schemes for the purpose of facilitating low income groups. For instance, the NBCCEDP scheme enables CDC to help people in low incomes who are underinsured or uninsured in gaining access to timely cervical and breast cancer screening, treatment, and diagnostic services. The scheme also provides patient navigation services in helping them to gain timely access to quality care and overcome barriers.
Prominent companies in the market include Abbott Molecular, F. Hoffmann-La Roche Ltd., OncoHealth Corporation, Dell Guided Therapeutics, CooperSurgical, Quest Diagnostics, QIAGEN, Arbor Vita Corporation, Hologic. These players are focused on R&D initiatives for the development of technologically advanced and innovative cervical cancer diagnostic systems and are also entering into collaborations for maintaining their position in the market.
For instance, in February 2021, Qiagen and Inovio Pharmaceuticals entered into an extended partnership for the development of liquid biopsy-based companion diagnostic products that are based on NGS (next-generation sequencing) technology for complementing Inovio’s therapies.
The COVID-19 pandemic has led to disruptions in elective health services associated with cervical screening, treatment of precancers, and the management of abnormal screening test results. This could lead to an upsurge in the incidences of cervical cancer, further increasing existing health disparities. Therefore, a number of organizations are devising approaches that can help in the mitigation of the disruption of cervical management and screening. Such efforts are poised to foster the demand for cervical cancer diagnostic tests during the forecast timeframe.
Market, by Test-type
The above information is provided for the following regions and countries: